Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 in progressive fibrosing interstitial lung diseases
MOH_2023-06-28_012773Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nerandomilast in progressive pulmonary fibrosis (PPF) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Primary endpoint not reported in registry entry. Started Jun 2023; status: active, not recruiting.
02
Drugs
nerandomilast
03
Conditions
progressive pulmonary fibrosis (PPF)
Beyond the preview
Go deeper on MOH_2023-06-28_012773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-28_012773.